A Lower Olfactory Capacity Is Related to Higher Circulating Concentrations of Endocannabinoid 2-Arachidonoylglycerol and Higher Body Mass Index in Women
Pastor A (1,2,3), Fernández-Aranda F (4,3), Fitó M (5,3), Jiménez-Murcia S (4,6,3), Botella C (7,3), Fernández-Real JM (8,3), Frühbeck G (9,3), Tinahones FJ (10,3), Fagundo AB (4), Rodriguez J (1), Agüera Z (4), Langohr K (1,11), Casanueva FF (12,3), de la Torre R (1,3,13).
(1) Integrative Pharmacology and Systems Neuroscience Research Group, Neuroscience Research Program, IMIM (Hospital de Mar Medical Research Institute), Barcelona, Spain.
(2) Department of Pharmacology, School of Medicine, Universitat Autònoma de Barcelona, Barcelona, Spain.
(3) CIBER Fisiopatología Obesidad y Nutrición (CIBERObn), Instituto Salud Carlos III, Madrid, Spain.
(4) Department of Psychiatry, University Hospital of Bellvitge-IDIBELL, Barcelona, Spain.
(5) Cardiovascular Risk and Nutrition Research Group, Inflammatory and Cardiovascular Disorders Research Program, IMIM (Hospital del Mar Medical Research Institute), Barcelona, Spain.
(6) Department of Clinical Sciences, School of Medicine, University of Barcelona, Barcelona, Spain.
(7) Department of Basic Psychology, Clinic and Psychobiology, University Jaume I, Castelló, Spain.
(8) Department of Diabetes, Endocrinology and Nutrition, Institut d'Investigació Biomèdica de Girona (IdlBGi), Hospital Dr Josep Trueta, Girona, Spain.
(9) Department of Endocrinology and Nutrition, Clínica Universidad de Navarra, University of Navarra, IdiSNA, Pamplona, Spain.
(10) Department of Diabetes, Endocrinology and Nutrition, Hospital Clínico Universitario Virgen de Victoria, Málaga, Spain.
(11) Department of Statistics and Operations Research, Universitat Politècnica de Catalunya, Barcelona, Spain.
(12) Endocrine Division, Complejo Hospitalario U. de Santiago, Santiago de Compostela University, Santiago de Compostela, Spain.
(13) Department of Experimental and Health Sciences, Universitat Pompeu Fabra, Barcelona, Spain.
Revista: PloS One
Fecha: 05-feb-2016Endocrinología y Nutrición Área de Obesidad
The endocannabinoid (eCB) system can promote food intake by increasing odor detection in mice. The eCB system is over-active in human obesity. Our aim is to measure circulating eCB concentrations and olfactory capacity in a human sample that includes people with obesity and explore the possible interaction between olfaction, obesity and the eCB system.
The study sample was made up of 161 females with five groups of body mass index sub-categories ranging from under-weight to morbidly obese.
We assessed olfactory capacity with the "Sniffin´Sticks" test, which measures olfactory threshold-discrimination-identification (TDI) capacity. We measured plasma concentrations of the eCBs 2-arachidonoylglycerol (2-AG) and N-arachidonoylethanolamine or anandamide (AEA), and several eCB-related compounds, 2-acylglycerols and N-acylethanolamines. 2-AG and other 2-acylglycerols fasting plasma circulating plasma concentrations were higher in obese and morbidly obese subjects. AEA and other N-acylethanolamine circulating concentrations were lower in under-weight subjects.
Olfactory TDI scores were lower in obese and morbidly obese subjects. Lower TDI scores were independently associated with higher 2-AG fasting plasma circulating concentrations, higher %body fat, and higher body mass index, after controlling for age, smoking, menstruation, and use of contraceptives.
Our results show that obese subjects have a lower olfactory capacity than non-obese ones and that elevated fasting plasma circulating 2-AG concentrations in obesity are linked to a lower olfactory capacity.
In agreement with previous studies we show that eCBs AEA and 2-AG, and their respective congeners have a distinct profile in relation to body mass index. The present report is the first study in humans in which olfactory capacity and circulating eCB concentrations have been measured in the same subjects.
CITA DEL ARTÍCULO PLoS One. 2016 Feb 5;11(2):e0148734. doi: 10.1371/journal.pone.0148734.
tal vezLE INTERESE
La Clínica es el hospital privado con mayor dotación tecnológica de España, todo en un único centro.
Los profesionales de la Clínica realizan una labor continuada de investigación y formación, siempre en beneficio del paciente.
Conozca por qué somos diferentes a otros centros sanitarios. Calidad, rapidez, comodidad y resultados.